Why are survivors of childhood cancer 15 times more likely to have heart failure? How can the incidence of cardiovascular disease, which is 8 times higher in childhood cancer survivors than the general population be reduced? How do we identify at risk patients earlier and provide the best management regimen to improve the long-term cardiovascular health of these children and AYA?
ACOR is a world first paediatric and young adult prospective cardio-oncology registry designed to capture the clinical, epidemiological and pharmaceutical data from every Australian child and young adult that receives cardiac toxic therapies (chemotherapy, radiotherapy, molecular and immunotherapy). This strategically places ACOR in a position to provide data to underpin research and generate hypotheses that will address some of the above questions.
- Survivors of childhood cancer are 15 times more likely to have heart failure
- The incidence of cardiovascular disease is 8 times higher in childhood cancer survivors
ACOR aims to provide a research platform from which longitudinal data can be attained and through which further research can be developed to better provide outcomes for children and young adults who are at risk of cancer therapy related cardiovascular dysfunction (CRTCD).